ABBOTT LABORATORIES (ABL.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ABL - US0028241000 - Common Stock
107.06 EUR
-0.12 (-0.11%)
Overall ABL gets a fundamental rating of 6 out of 10. We evaluated ABL against 65 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making ABL a very profitable company, without any liquidiy or solvency issues. While showing a medium growth rate, ABL is valued expensive at the moment. These ratings would make ABL suitable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year ABL was profitable.
In the past year ABL had a positive cash flow from operations.
In the past 5 years ABL has always been profitable.
ABL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ABL has a Return On Assets of 16.60%. This is amongst the best in the industry. ABL outperforms 93.85% of its industry peers.
Looking at the Return On Equity, with a value of 27.43%, ABL belongs to the top of the industry, outperforming 95.38% of the companies in the same industry.
ABL has a better Return On Invested Capital (9.90%) than 80.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ABL is in line with the industry average of 9.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.6% | ||
| ROE | 27.43% | ||
| ROIC | 9.9% |
ROA(3y)11.2%
ROA(5y)9.84%
ROE(3y)20.61%
ROE(5y)19.06%
ROIC(3y)10.45%
ROIC(5y)10.18%
1.3 Margins
ABL's Profit Margin of 31.88% is amongst the best of the industry. ABL outperforms 100.00% of its industry peers.
ABL's Profit Margin has improved in the last couple of years.
ABL has a better Operating Margin (18.29%) than 75.38% of its industry peers.
In the last couple of years the Operating Margin of ABL has grown nicely.
ABL has a Gross Margin (56.19%) which is comparable to the rest of the industry.
ABL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.29% | ||
| PM (TTM) | 31.88% | ||
| GM | 56.19% |
OM growth 3Y-5.79%
OM growth 5Y2.63%
PM growth 3Y24.85%
PM growth 5Y22.55%
GM growth 3Y-0.89%
GM growth 5Y-1.07%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ABL is creating some value.
ABL has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ABL has less shares outstanding
ABL has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.75 indicates that ABL is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.75, ABL belongs to the best of the industry, outperforming 89.23% of the companies in the same industry.
ABL has a debt to FCF ratio of 1.87. This is a very positive value and a sign of high solvency as it would only need 1.87 years to pay back of all of its debts.
ABL has a better Debt to FCF ratio (1.87) than 83.08% of its industry peers.
ABL has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ABL (0.23) is better than 69.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 1.87 | ||
| Altman-Z | 5.75 |
ROIC/WACC1.17
WACC8.44%
2.3 Liquidity
A Current Ratio of 1.70 indicates that ABL should not have too much problems paying its short term obligations.
With a Current ratio value of 1.70, ABL perfoms like the industry average, outperforming 53.85% of the companies in the same industry.
A Quick Ratio of 1.24 indicates that ABL should not have too much problems paying its short term obligations.
ABL has a Quick ratio of 1.24. This is comparable to the rest of the industry: ABL outperforms 56.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.24 |
3. Growth
3.1 Past
ABL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.40%, which is quite good.
The Earnings Per Share has been growing slightly by 7.59% on average over the past years.
ABL shows a small growth in Revenue. In the last year, the Revenue has grown by 6.37%.
The Revenue has been growing slightly by 5.63% on average over the past years.
EPS 1Y (TTM)10.4%
EPS 3Y-3.58%
EPS 5Y7.59%
EPS Q2Q%7.44%
Revenue 1Y (TTM)6.37%
Revenue growth 3Y-0.88%
Revenue growth 5Y5.63%
Sales Q2Q%6.9%
3.2 Future
ABL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.89% yearly.
The Revenue is expected to grow by 7.22% on average over the next years.
EPS Next Y11.44%
EPS Next 2Y10.8%
EPS Next 3Y10.58%
EPS Next 5Y9.89%
Revenue Next Year6.44%
Revenue Next 2Y7.19%
Revenue Next 3Y7.32%
Revenue Next 5Y7.22%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 25.19, ABL can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of ABL indicates a somewhat cheap valuation: ABL is cheaper than 66.15% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.61. ABL is around the same levels.
With a Price/Forward Earnings ratio of 21.93, ABL is valued on the expensive side.
ABL's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of ABL to the average of the S&P500 Index (24.01), we can say ABL is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.19 | ||
| Fwd PE | 21.93 |
4.2 Price Multiples
ABL's Enterprise Value to EBITDA is on the same level as the industry average.
Based on the Price/Free Cash Flow ratio, ABL is valued a bit cheaper than the industry average as 64.62% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.61 | ||
| EV/EBITDA | 20.08 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ABL has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.2
PEG (5Y)3.32
EPS Next 2Y10.8%
EPS Next 3Y10.58%
5. Dividend
5.1 Amount
ABL has a Yearly Dividend Yield of 2.01%. Purely for dividend investing, there may be better candidates out there.
ABL's Dividend Yield is a higher than the industry average which is at 1.03.
Compared to an average S&P500 Dividend Yield of 1.87, ABL has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.01% |
5.2 History
The dividend of ABL is nicely growing with an annual growth rate of 11.40%!
Dividend Growth(5Y)11.4%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
28.93% of the earnings are spent on dividend by ABL. This is a low number and sustainable payout ratio.
ABL's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP28.93%
EPS Next 2Y10.8%
EPS Next 3Y10.58%
FRA:ABL (12/23/2025, 10:02:01 AM)
107.06
-0.12 (-0.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners81.17%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap186.16B
Revenue(TTM)43.84B
Net Income(TTM)13.98B
Analysts79.43
Price Target124.8 (16.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.01% |
Yearly Dividend1.89
Dividend Growth(5Y)11.4%
DP28.93%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.82%
Min EPS beat(2)-1.06%
Max EPS beat(2)-0.58%
EPS beat(4)1
Avg EPS beat(4)-0.52%
Min EPS beat(4)-1.16%
Max EPS beat(4)0.73%
EPS beat(8)3
Avg EPS beat(8)0.07%
EPS beat(12)7
Avg EPS beat(12)1.63%
EPS beat(16)11
Avg EPS beat(16)5.69%
Revenue beat(2)0
Avg Revenue beat(2)-0.81%
Min Revenue beat(2)-1.29%
Max Revenue beat(2)-0.33%
Revenue beat(4)0
Avg Revenue beat(4)-1.08%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)-0.33%
Revenue beat(8)0
Avg Revenue beat(8)-0.75%
Revenue beat(12)4
Avg Revenue beat(12)0.15%
Revenue beat(16)8
Avg Revenue beat(16)1.85%
PT rev (1m)-1.5%
PT rev (3m)1.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.48%
EPS NY rev (1m)0%
EPS NY rev (3m)0.15%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.19 | ||
| Fwd PE | 21.93 | ||
| P/S | 4.99 | ||
| P/FCF | 31.61 | ||
| P/OCF | 23.98 | ||
| P/B | 4.29 | ||
| P/tB | 10.22 | ||
| EV/EBITDA | 20.08 |
EPS(TTM)4.25
EY3.97%
EPS(NY)4.88
Fwd EY4.56%
FCF(TTM)3.39
FCFY3.16%
OCF(TTM)4.47
OCFY4.17%
SpS21.47
BVpS24.95
TBVpS10.47
PEG (NY)2.2
PEG (5Y)3.32
Graham Number48.84
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.6% | ||
| ROE | 27.43% | ||
| ROCE | 11.52% | ||
| ROIC | 9.9% | ||
| ROICexc | 11.13% | ||
| ROICexgc | 21.33% | ||
| OM | 18.29% | ||
| PM (TTM) | 31.88% | ||
| GM | 56.19% | ||
| FCFM | 15.78% |
ROA(3y)11.2%
ROA(5y)9.84%
ROE(3y)20.61%
ROE(5y)19.06%
ROIC(3y)10.45%
ROIC(5y)10.18%
ROICexc(3y)12.18%
ROICexc(5y)11.89%
ROICexgc(3y)32.65%
ROICexgc(5y)35.03%
ROCE(3y)12.16%
ROCE(5y)11.86%
ROICexgc growth 3Y-24.08%
ROICexgc growth 5Y-8.19%
ROICexc growth 3Y-10.71%
ROICexc growth 5Y6.04%
OM growth 3Y-5.79%
OM growth 5Y2.63%
PM growth 3Y24.85%
PM growth 5Y22.55%
GM growth 3Y-0.89%
GM growth 5Y-1.07%
F-Score7
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 1.87 | ||
| Debt/EBITDA | 1.04 | ||
| Cap/Depr | 70.33% | ||
| Cap/Sales | 5.02% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 81.77% | ||
| Profit Quality | 49.49% | ||
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.24 | ||
| Altman-Z | 5.75 |
F-Score7
WACC8.44%
ROIC/WACC1.17
Cap/Depr(3y)63.63%
Cap/Depr(5y)61.92%
Cap/Sales(3y)4.94%
Cap/Sales(5y)5.1%
Profit Quality(3y)82.78%
Profit Quality(5y)99.6%
High Growth Momentum
Growth
EPS 1Y (TTM)10.4%
EPS 3Y-3.58%
EPS 5Y7.59%
EPS Q2Q%7.44%
EPS Next Y11.44%
EPS Next 2Y10.8%
EPS Next 3Y10.58%
EPS Next 5Y9.89%
Revenue 1Y (TTM)6.37%
Revenue growth 3Y-0.88%
Revenue growth 5Y5.63%
Sales Q2Q%6.9%
Revenue Next Year6.44%
Revenue Next 2Y7.19%
Revenue Next 3Y7.32%
Revenue Next 5Y7.22%
EBIT growth 1Y15.18%
EBIT growth 3Y-6.62%
EBIT growth 5Y8.41%
EBIT Next Year27.08%
EBIT Next 3Y15.42%
EBIT Next 5Y13.66%
FCF growth 1Y53.98%
FCF growth 3Y-9.78%
FCF growth 5Y7.14%
OCF growth 1Y39.24%
OCF growth 3Y-6.69%
OCF growth 5Y6.88%
ABBOTT LABORATORIES / ABL.DE FAQ
What is the fundamental rating for ABL stock?
ChartMill assigns a fundamental rating of 6 / 10 to ABL.DE.
What is the valuation status for ABL stock?
ChartMill assigns a valuation rating of 3 / 10 to ABBOTT LABORATORIES (ABL.DE). This can be considered as Overvalued.
What is the profitability of ABL stock?
ABBOTT LABORATORIES (ABL.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of ABBOTT LABORATORIES (ABL.DE) stock?
The Price/Earnings (PE) ratio for ABBOTT LABORATORIES (ABL.DE) is 25.19 and the Price/Book (PB) ratio is 4.29.
Can you provide the financial health for ABL stock?
The financial health rating of ABBOTT LABORATORIES (ABL.DE) is 7 / 10.